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ABSTRACT
Objective: We sought to determine 1) long-term lipid-
lowering treatment patterns; 2) cholesterol goal attainment
rates and possible determinants of goal achievement; and 3)
effects of cholesterol goal attainment on coronary events in
hospitalized Hong Kong patients.
Methods: In this retrospective cohort analysis, records of
two public Hong Kong hospitals were reviewed for 196
adults (69% with coronary heart disease (CHD) or CHD-
risk equivalent) who received at least one lipid-lowering
therapy during hospitalization. Low-density lipoprotein cho-
lesterol (LDL-C) targets were <2.6 mmol/l (<100 mg/dL)
for patients with CHD or CHD risk equivalents and
<3.37 mmol/l (<130 mg/dL) for those without.
Results: Most participants were initiated on regimens of low
to midequipotency doses and never had their regimens
adjusted to higher potency. Approximately 44% of patients
not at LDL-C at baseline failed to achieve goal during a
median follow-up of 1.9 years. Patients with higher coronary
risk and/or LDL-C levels at baseline were less likely than their
lower-risk counterparts to achieve goal; for each 1-mmol/l
(38.7-mg/dL) increase in LDL-C at baseline, the likelihood of
attaining goal declined by 64%. Patients achieving choles-
terol goal had signiﬁcantly longer cardiovascular event-free
times.
Conclusions: A total of 44% of Hong Kong patients not at
LDL-C goals at baseline did not achieve them over 1.9 years.
More effective and well-tolerated therapies, including ad-
junctive regimens (e.g., ezetimibe-statin, niacin-statin),may be
necessary to enhance LDL-C goal achievement and increase
event-free time.
Keywords: coronary disease, hydroxymethylglutaryl CoA
reductase inhibitors, hypercholesterolemia, prevention and
control.
Introduction
Cardiovascular disease, including coronary heart
disease (CHD) and stroke, is a leading cause of mor-
bidity and mortality. Each year, these conditions
account for 17 million deaths worldwide [1]. In Hong
Kong, since the 1960s, CHD has been second only to
cancer as the most common cause of death [2], and it
is the most common organ-speciﬁc cause of death [3].
Although the mortality rate associated with CHD has
markedly declined in the United States and parts of
Western Europe during the past 40 years, the rate has
been increasing in Hong Kong [3].
Coronary heart disease is a major cause of both
mortality and morbidity in Hong Kong. According to
2003 estimates, each year, heart disease accounted for
14.6% of all deaths, and diseases of the circulatory
system accounted for 8.5% of all hospitalizations
(~103,000 of 1.2 million) [4]. In addition, CHD is a
major source of health-care expenditures. In 2000 to
2001, the total cost of managing acute myocardial
infarction (MI) alone was $45 million (HKD 349
million), or 0.5% of total health-care expenditures [5].
Nevertheless, absolute cardiovascular risk is a continu-
ous rather than a categorical variable, and even
patients without prior CHD may be at increased risk
because of major cardiovascular risk factors (e.g.,
smoking, hypertension).
Chinese populations have traditionally been per-
ceived to have lower cholesterol levels than Caucasians
[6–8]. Nevertheless, rapid economic growth and
urbanization in recent decades have been associated
with a high prevalence of CHD and cholesterol levels
in Hong Kong. As of 2003/2004, life expectancy at
birth was higher in Hong Kong than in the United
States for both males (78.5 years) and females
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(84.3 years), and the burden of chronic diseases
(including CHD) is known to increase with rising life
expectancy [4]. A recent long-term study showed that
54.2% of 17,716 participants had a total cholesterol
level >5.2 mmol/l (>200 mg/dL), and 44.3% (includ-
ing 41.5% of men) had 10-year absolute coronary
risk 20% [9].
Landmark randomized controlled trials have dem-
onstrated that intensive lipid-lowering therapy signiﬁ-
cantly reduces cardiovascular events and progression
of coronary atherosclerosis compared with more mod-
erate regimens [10–12]. These and other ﬁndings led a
US consensus panel to urge consideration of new,
lower targets for low-density lipoprotein cholesterol
(LDL-C) among certain high-risk patients [13]. Never-
theless, recent studies have shown that patients are not
being treated even to older, less aggressive cholesterol
goals and that lipid-lowering treatments are domi-
nated by statin monotherapy prescribed at low- to
moderate-equidose potency [14–19].
The objectives of the Hong Kong Hospital Audit
Study were to determine 1) long-term lipid-lowering
treatment patterns; 2) cholesterol goal attainment rates
and possible determinants of goal achievement; and 3)
effects of cholesterol goal attainment on coronary
events in hospitalized Hong Kong patients.
Methods
The Hong Kong Hospital Audit Study was a 2-year
multicenter, retrospective cohort analysis involving
medical records of two public Hong Kong hospitals.
Records of patients who had been admitted to the
emergency department secondary to acute MI were
identiﬁed by computer database system at the two
centers.
Patients
Study participants were adults (>18 years of age) who
had been hospitalized between January 2001 and
December 2002 and had admission LDL-C >
2.59 mmol/l (>100 mg/dL). Participants must not have
used lipid-lowering medication for at least 6 months
prior to admission (baseline period; Fig. 1). Lipid-
lowering drug therapy was initiated during the
hospital stay, and eligible patients remained on lipid-
lowering therapy for at least 3 months after discharge.
Data Collection
This study was conducted at two of the largest acute-
care regional hospitals in Hong Kong. One is located
in a recently developed satellite town and the other is
in a relatively old part of the city. Data collected are
hence reasonably representative of the general popula-
tion of Hong Kong. Anonymized case notes of patients
with acute MI who were admitted during the speciﬁed
period were identiﬁed using the computer system of
the two hospitals. Patients with complete records for at
least 2 years after the index date were recruited in the
study.
Data were collected at baseline, or within 6 months
before the index prescription date (Fig. 1). The index
prescription date was deﬁned as the date of the ﬁrst
lipid-lowering medication prescription. Initial lipid-
lowering therapies were categorized by 1) equidose
potency according to Maron’s formulation [19]; and
2) each patient’s baseline LDL-C category: category
1 < 3.2 mmol/l (<125 mg/dL), category 2 = 3.2 mmol/l
to 4.5 mmol/l (125–175 mg/dL), and category 3 > 4.5
mmol/l (>175 mg/dL). Baseline data were collected in
part to conﬁrm that the patient had not received lipid-
lowering therapy. Data collected during the study
period (median = 1.9 years) included LDL-C goal
attainment (see below), changes in equipotency doses,
and coronary events. All recruited patients were fol-
lowed up by cardiologists at the two centers, such that
patients’ medical records included both inpatient and
outpatient data.
Cholesterol Goal Attainment
For patients with CHD or CHD-risk equivalents, the
LDL-C goal was <2.6 mmol/l (<100 mg/dL) [20].
Patients with CHD had MI, angina pectoris, or a
history of coronary revascularization (percutaneous
coronary intervention, coronary artery bypass graft-
ing), while patients with CHD risk equivalents had
diabetes mellitus, stroke, and/or peripheral vascular
disease. For high-risk non-CHD patients, the LDL-C
goal was <3.37 mmol/l (<130 mg/dL) [20].
Statistical Methods
Patients were risk-stratiﬁed based on baseline data as
CHD/CHD equivalent or high-risk non-CHD. Goal
attainment was evaluated at 3-month intervals until
the ﬁnal follow-up laboratory results were obtained.
Nevertheless, not all patients had a cholesterol goal
measurement at each 3-month point because this was a
clinic-based study and not performed according to a
protocol with scheduled assessments.
For patients with missing data, the most recent
laboratory data were carried forward as the endpoint
values. Factors associated with LDL-C goal attainmentFigure 1 Study design.
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were evaluated using logistic regression analysis. The
logistic model included age, sex, baseline smoking,
baseline drinking, baseline hypertension, baseline dia-
betes mellitus, baseline CHD, baseline LDL-C, base-
line lipid-lowering equidose potency [19], and changes
in equidose potency during study follow-up. Odds
ratios (ORs) and 95% conﬁdence intervals (CIs) were
computed.
Kaplan–Meier estimates were used to evaluate the
impact of LDL-C goal attainment prior to event on
event-free time (time to initial or subsequent event
posthospitalization). Signiﬁcance was at two-tailed
a = 0.05. SAS version 8.02 (SAS Institute, Cary, NC)
was used for statistical analyses.
Results
Patients
A total of 315 patient records were identiﬁed ran-
domly from the two hospitals. Three of these were
excluded because of inconsistent data. Twenty-one
others were omitted because of patient death within
30 days of admission. Of the remaining 291 patients,
196 received at least one lipid-lowering therapy during
their hospital stay and comprise the study population.
Baseline characteristics for patients with or without
CHD are summarized in Table 1. Approximately 69%
of patients had CHD or a CHD-risk equivalent,
and 46% had hypertension. The mean LDL-C was
3.92 mmol/l (152 mg/dL), and the mean total choles-
terol was 5.47 mmol/l (212 mg/dL).
Lipid-Lowering Therapy
Initial lipid-lowering therapy by baseline LDL-C is
presented in Figure 2 and Table 2. Overall, most regi-
mens were initiated at low to midequipotency doses
(potency  3), with initial potency of 0 to 3 in 152
(78%) of patients. Frequencies of very high equipo-
tency dose regimens (potency 5) increased across rising
LDL-C categories.
Changes in lipid-lowering therapy are shown in
Table 2. Changes in equidose potency were infrequent.
Approximately 60% of the initial regimens remained
unchanged during the study period. Downtitration
was relatively common in patients receiving high or
very high equipotency dose treatments, occurring in
Table 1 Baseline characteristics
Characteristic
CHD/CHD-equivalent
group (N = 135)
Non-CHD high
risk group (N = 61)
All patients
(N = 196)
Mean (SD) age, year 63.70 (11.26) 61.15 (13.69) 62.90 (12.09)
No. (%) male 97 (71.85) 47 (77.05) 144 (73.5)
Mean (SD) TC, mmol/L 5.38 (1.23) 5.64 (1.21) 5.47 (1.22)
Mean (SD) LDL-C, mmol/L 3.41 (1.0) 3.71 (1.06) 3.92 (1.09)
Mean (SD) HDL-C, mmol/L 1.15 (0.32) 1.19 (0.35) 1.16 (0.33)
Mean (SD) triglycerides, mmol/L 1.89 (1.03) 1.66 (0.77) 1.81 (0.96)
No. (%) with CHD or CHD risk equivalent 135 (100) NA 135 (68.9)
No. (%) with diabetes mellitus 60 (44.44) NA 60 (30.6)
No. (%) with hypertension 66 (49.25) 25 (40.98) 91 (46.4)
No. (%) current smokers 76 (56.30) 39 (63.93) 115 (58.7)
No. (%) consuming alcohol* 16 (11.85) 8 (13.11) 24 (12.2)
*Patients reporting being “social” or “heavy” drinkers (number of units per week not quantiﬁed).
CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;TC, total cholesterol.
Potency 0 = fibratesand resins, Potency 1 = Pravastatin 10 mg or equipotent, Potency  2 = simvastatin 10 mg or equipotent, 











            LDL-C category-1
(LDL-C < 3.25 mmol/L)
            LDL-C category-2           
(LDL-C of 3.21 - 4.54 mmol/L)
LDL-C category-3
(LDL-C > 4.54 mmol/L)
Potency 0 Potency 1 Potency 2
Potency 3 Potency 4 Potency 5
Figure 2 Initial lipid-lowering therapy by base-
line low-density lipoprotein cholesterol
(LDL-C) category. Category 1: LDL-C
< 3.2 mmol/l (<125 mg/dL), category 2: LDL-C
3.2–4.5 mmol/l (125–176 mg/dL), category 3:
LDL-C > 4.5 mmol/l (>176 mg/dL). Equidose
potencies by Maron’s formulation [19].
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approximately 24% of equipotency-dose 4 and 40%
of equipotency-dose 5 regimens.
Cholesterol Goal Attainment
As shown in Figure 3, 55.8% of patients not at goal at
baseline (60.1% of all patients) achieved LDL-C goals
after 1.9 years of follow-up (or at the most recent
laboratory measurement carried forward in patients
without endpoint data). Patients in the highest LDL-
C category (>4.5 mmol/l [>175 mg/dL]) were least
likely to achieve their LDL-C goals (Fig. 3A). LDL-C
goal attainment tended to be less frequent with
increasing lipid-lowering regimen equidose potency
(Fig. 3B) and was lowest among patients who received
very high equipotency dose regimens (<8%). Neverthe-
less, high equipotency doses were more commonly
used in patients with high baseline LDL-C (Fig. 3A).
Based on logistic regression analysis, CHD/CHD
equivalent patients were at lower odds of goal attain-
ment compared with non-CHD patients (Table 3). The
OR of goal attainment was 19% lower for CHD/
CHD-equivalent patients compared with individuals
without CHD or CHD risk equivalents (95%
CI = 0.080–0.459). The only other factor impacting
goal attainment apart from baseline CHD risk
(Table 3) was baseline LDL-C concentration. Increases
in baseline LDL-C levels signiﬁcantly reduced the odds
of goal attainment. For each increase of 1 mmol/l in
baseline LDL-C, there was a 64% lower odds of
attaining LDL-C goal (95% CI = 0.449–0.904).
Patients who attained LDL-C goal had signiﬁcantly
longer event-free time (time before experiencing a sub-
sequent event or recurrent event posthospitalization
and hence this can be stated as time to subsequent




0 1 2 3 4 5
0 (n = 2) 50.0 0 50.0 0 0 0
1 (n = 25) 0 60.0 24.0 12.0 4.0 0
2 (n = 61) 0 8.2 62.3 18.0 8.2 3.3
3 (n = 64) 0 7.8 18.8 53.1 17.2 3.1
4 (n = 33) 0 6.1 9.1 9.1 69.7 6.1
5 (n = 10) 0 0 0 30.0 10.0 60.0
*Equidose potency according to Maron’s formulation [19].
†N-values in ﬁrst column total 195 instead of 196 because there was 1 patient with
missing information regarding dose.
Figure 3 Low-density lipoprotein cholesterol
(LDL-C) goal attainment by LDL-C category
(A) and baseline equipotency dose (B). For deﬁ-
nitions of LDL-C categories, see Figure 2
legend. Statin equidose potency according to
Maron’s formulation [19].
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event) compared with patients who did not attain goal.
The Kaplan-Meier hazard plot shown in Figure 4 dem-
onstrates a signiﬁcant increase in cardiovascular event-
free time (or time to event) for patients achieving
LDL-C goals. The time until the ﬁrst 25% of events
was 69 days for those achieving goal compared with
27 days for those not achieving goal (P < 0.05). The
median event-free time in patients achieving LDL-C
goal (396 days) was signiﬁcantly higher compared
with patients not achieving goal (61 days).
Discussion
The Hong Kong Hospital Audit Study demonstrated
that 44% of hospitalized patients not at LDL-C goal at
baseline failed to achieve their cholesterol goals by a
median follow-up of 1.9 years. Goal achievement was
signiﬁcantly less frequent among patients with CHD/
CHD risk equivalents (OR = 0.210) and/or elevated
LDL-C levels. For each 1-mmol/l (38.7-mg/dL) in-
crease in baseline LDL-C, the likelihood of achieving
goal declined by 64%. Patients who achieved LDL-C
goals had signiﬁcantly reduced risks of coronary events
and signiﬁcantly longer cardiovascular event-free times
than those who did not. Goal achievement may be
particularly difﬁcult in patients with CHD and CHD-
risk equivalents in part because of both their fre-
quently elevated baseline LDL-C levels and their more
stringent LDL-C goals compared with patients having
risk factors only.
Lipid-lowering treatment was dominated by low to
medium equidose-potency regimens, most of which
(>60%) were never adjusted to higher doses. Goal
achievement did not tend to increase with increasing
baseline lipid-lowering regimen potency; for instance,
<8% of patients receiving very high equipotency dose
regimens achieved LDL-C goal. The low goal attain-
ment among patients receiving very high equipotency
dose treatments is probably confounded by increased
coronary risk and/or LDL-C levels in these patients,
with the high equidose potency being a probable
surrogate for advanced risk (and/or very elevated
LDL-C). Neither baseline lipid-lowering treatment
equidose potency nor changes in potency during the
study were associated with any signiﬁcant reduction
in coronary events. In addition, 24% to 40% of
high equipotency regimens needed to be adjusted
downward.
Table 3 Results of logistic regression analysis: odds ratios
(ORs) and 95% conﬁdence intervals (95% CIs) for cholesterol
goal attainment according to factors in the model




Consumer of alcohol§ 1.840 0.557–6.075
Hypertension¶ 1.311 0.622–2.764
CHD/CHD equivalent** 0.192 0.080–0.459
Baseline LDL-C†† 0.637 0.449–0.904
Initial Stain Potency = 2‡‡ 3.348 1.048–10.695
Initial Statin Potency = 3‡‡ 1.938 0.603–6.228
Initial Statin Potency = 4‡‡ 3.656 0.933–14.329
Initial Statin Potency = 5¶ 3.667 0.527–25.530
Potency Change (vs. no change) 1.153 0.766–1.733
*For each increasing year; †vs. males; ‡vs. nonsmokers; §vs. nonconsumer of alcohol;
¶vs. normotensive; **vs. without CHD or CHD risk equivalents; ††for each increase of
1 mmol/l (38 mg/dL); ‡‡vs. potency = 1 (low potency).
CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol.
Follow-up CVD Events By Goal Attainment














Results: Kaplan Meier Curves for Event Free Time
Figure 4 Kaplan–Meier hazard plots for car-
diovascular event-free time in patients who
achieved or did not achieve low-density lipo-
protein cholesterol goals. CVD, cardiovascular
disease.
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Suboptimal clinical management of dyslipidemia,
including the use of predominantly low to midequipo-
tency dose regimens, infrequent dose adjustment,
and use of combination regimens, suboptimal goal
achievement, and particularly low goal attainment with
increasing baseline coronary risk and/or LDL-C levels
observed in the Hong Kong Hospital Audit Study
extend ﬁndings of previous studies [14,15,17,18,21–
26]. In addition, prior work demonstrated signiﬁcant
reductions in the risk of cardiovascular events in
patients achieving cholesterol goals [27–29]. For
instance, the Return on Expenditure Achieved for Lipid
Therapy (REALITY-Sweden) study showed that
patients achieving cholesterol goals were 24% less
likely to experience a cardiovascular event compared
with their counterparts who did not attain goal [29].
Uptitration of statin monotherapy is of limited incre-
mental value in lowering cholesterol [30,31] and may
be associated with increasing frequencies of adverse
effects. Though intriguing, our ﬁndings of suboptimal
cholesterol goal attainment in patients receiving high-
dose lipid-loweringmonotherapy, whichmay be largely
secondary to high baseline LDL-C levels and/or abso-
lute cardiovascular risk in these patients, need to be
evaluated further in larger, well-controlled studies
involving a more heterogeneous patient population fol-
lowed up for a longer interval.
To achieve increasingly aggressive consensus cho-
lesterol targets [13,32], new clinical strategies are
warranted. One proven approach to enhance goal
achievement is dual cholesterol inhibition [33–37].
Although 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMG-CoA) reductase inhibitors (statins)
effectively inhibit the rate-limiting enzyme in hepatic
cholesterol biosynthesis, dietary and biliary absorption
of cholesterol accounts for an equivalent portion of
circulating cholesterol [38]. Via interaction with the
NPC1L1 protein, ezetimibe inhibits absorption of cho-
lesterol from the gastrointestinal tract [39].
Relevant studies have shown signiﬁcant increases
in LDL-C-lowering capacity [40,41] and cholesterol
goal achievement with ezetimibe statins compared
with statin monotherapy (with or without titration) in
patients not at goal on statin monotherapy. Gagné
et al. observed that ezetimibe-statins were associated
with a goal attainment rate of 71.5% compared with
only 18.9% for ongoing statin treatment plus placebo
(P < 0.001) [33]. In the Ezetimibe add-on to statin
for effectiveness trial, 71.0% of patients receiving
ezetimibe-statins met their LDL-C goal, whereas only
20.6% of those on placebo-statin obtained goal
(P < 0.001) [35]. In the Vytorin Versus Atorvastatin
study, 85.4% of patients with CHD or CHD risk
equivalents achieved the LDL-C goal of <2.6 mmol/l
(<100 mg/dL) using ezetimibe-simvastatin compared
with 70.0% of those using atorvastatin alone (P <
0.001) [36].
Potential approaches to enhance goal achievement
also include other adjunctive regimens, such as niacin-
statins [42] and ezetimibe bile acid resins (seques-
trants) [43]. Behavioral techniques also have been
used. In a previous Hong Kong study, 80.8% of
patients who received lipid-modifying therapies (for
primary prevention) with individualized counseling by
pharmacists achieved their consensus cholesterol goals
compared with 58.3% of those in the noncounseled
control group [44].
Limitations of the present study include its retro-
spective design and relatively small patient population,
which leaves open the possibility of type II error.
Further, the small patient population was evaluated
in an acute-care setting and included patients at high
coronary risk (mostly hospitalized patients with
CHD). Therefore, the ﬁndings are not necessarily gen-
eralizable to the Hong Kong ambulatory-care popula-
tion at large but rather toward those in similar
hospitals. By studying an in-hospital population, we
cannot exclude certain biases. Standing medical orders
for, and scheduled dosing of, lipid-modifying therapies
might have helped to promote cholesterol goal
achievement through enhanced medication compli-
ance. This might have led to our overestimating
percent goal attainment in the overall (ambulatory-
care) population.
The duration of follow-up was also relatively short
at approximately 2 years. LDL-C goal achievement is
difﬁcult to maintain over the long term [27]. The goal
achievement rate of approximately 56% at approxi-
mately 2 years in the Hong Kong Hospital Audit Study
may thus overestimate longer-term goal attainment
rates. The limited baseline period (6 months) may have
led to an underestimation of patients with CHD/CHD
risk equivalents. This in turn might also have resulted
in the 56% goal attainment being an overestimation
given that patients at higher risk (e.g., CHD patients)
were less likely to achieve goal. Finally, the present
study did not assess the effects on goal attainment and
cardiovascular risk reduction of different levels of
compliance, which is known to be suboptimal in
patients receiving lipid-lowering therapies [45,46].
Conclusions
In the Hong Kong Hospital Audit Study, 44% of hos-
pitalized patients not at cholesterol goals at baseline
did not achieve their consensus LDL-C targets. Most
participants were initiated on regimens of low to mid-
equipotency doses and never had their regimens
adjusted to higher potency. Patients with higher base-
line coronary risk and/or LDL-C levels were less likely
than their lower-risk counterparts to achieve goals.
For every 1 mmol/l (38.7 mg/dL) increase in baseline
LDL-C, the likelihood of attaining goal declined by
64%. Patients achieving goals had signiﬁcantly longer
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times to cardiovascular events. More effective and
well-tolerated therapies, including adjunctive regimens
(e.g., ezetimibe-statins, niacin-statins), may be neces-
sary to enhance LDL-C goal achievement and delay
coronary events in Hong Kong patients.
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